Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Frontera London

- PMLiVE

PM Society Digital Awards 2024 – winners announced

Syneos Health Communications and Precision AQ led the agency list, while Novartis, Roche and Takeda shared the top client spot

- PMLiVE

Making at Impact at the Alliance Industry Summit

The Medscape team will be returning to the Alliance Industry Summit in Philadelphia this year, bringing with them Best in Class Outcomes and support for the event. As part of...

Medscape Education

Considerations for Planning Effective and Appealing Advisory Boards: Importance of Participant Preferences

Explore our peer-reviewed article, "Considerations for Planning Effective and Appealing Advisory Boards and Other Small-Group Meetings with Health Care Providers: Importance of Participant Preferences." Dive into key findings on HCPs'...

Impetus Digital

Reducing Carbon Footprint with Virtual Meetings – Perks of Virtual Medical Education

Discover how replacing in-person meetings with virtual alternatives can significantly cut carbon emissions and support environmental initiatives. Our latest video highlights the crucial role of virtual meetings in reducing the...

Impetus Digital

- PMLiVE

Johnson & Johnson’s IL-23 inhibitor Tremfya granted FDA approval for ulcerative colitis

The inflammatory bowel disease is estimated to affect more than one million people in the US

- PMLiVE

Pfizer’s Elrexfio accepted by SMC to treat relapsed and refractory multiple myeloma

Approximately 475 new cases of the disease are diagnosed in Scotland every year

- PMLiVE

Sanofi/Regeneron’s Dupixent approved by MHRA to treat uncontrolled COPD

Approximately 1.4 million people in the UK have been diagnosed with the respiratory disease

- PMLiVE

Climate of Health: the prescription for survival

Addressing climate change as a health crisis

- PMLiVE

Answering some of Pharma’s big questions to drive brand strategies

By James Aird and Zoë van Helmond

Amiculum

- PMLiVE

Gilead and AI-focused Genesis partner to develop small molecule therapies

The companies will use Genesis’ AI platform to generate and optimise molecules for targets selected by Gilead

- PMLiVE

Merck and Daiichi Sankyo’s ADC candidate ifinatamab deruxtecan shows promise in SCLC

Approximately 70% of small cell lung cancer patients are diagnosed with extensive-stage disease

- PMLiVE

Sanofi/Regeneron announce positive late-stage results for Dupixent in chronic spontaneous urticaria

Detailed results from the confirmatory trial will be submitted to the FDA later this year

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links